Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: A randomized, double-blind, placebo-controlled study

Diabetes Care

Volumn 31, Issue 12, 2008, Pages 2315-2317

  Defronzo, Ralph A ^a   Fleck, Penny R ^b   Wilson, Craig A ^b   Mekki, Qais ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BIOASSAY; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INFECTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SKIN PRURITUS; SUBCORNEAL PUSTULAR DERMATOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PIPERIDINES; URACIL;

EID: 58149171060     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1035     Document Type: Article

References (15)

1. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705, 2006
2. Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL 2nd: Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 50:2297-2300, 2007
3. Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase 4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled multiple-dose study in adult patients with type 2 diabetes. Clin Ther 30:499-512, 2008
4. European Medicines Agency: European public assessment report for Galvus-scientific discussion, 2007. Available from http://www.emea.europa.eu/ humandocs/ PDFs/EPAR/galvus/H-771-en6.pdf. Accessed 29 July 2008
5. Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ: Pharmacoki- netic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 589:306-314, 2008
6. Sato K, Ozaki H, Salamon CM, Christopher RJ, Yamamoto M: Lack of dermal toxicity with the highly selective dipepti- dyl peptidase-4 inhibitor alogliptin in monkeys (Abstract). Diabetes 57 (Suppl. 1): A580, 2008
7. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL: Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147: 386-399, 2007
8. Barnett A, Allsworth J, Jameson K, Mann R: A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 23:1493-1507, 2007
9. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, the Sitagliptin Study 021 Group: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632-2637, 2006
10. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38:423-428, 2006
11. Scott R, Wu M, Sanchez M, Stein P: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as mono- therapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61:171-180, 2007
12. Pi-SunyerFX, SchweizerA, MillsD, Dejager S: Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 76: 132-138, 2007
13. Dejager S, Razac S, Foley JE, Schweizer A: Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 39:218-223, 2007
14. Bosi E, Camisasca RP, Collober C, Roch- otte E, Garber AJ: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30: 890-895, 2007
15. DeFronzo RA, Hissa M, Blauwet MB, Chen RS: Saxagliptin added to metformin improves glycemic control in patients with type 2 diabetes (Abstract). Diabetes 56 (Suppl. 1):A74, 2007